SCHEMBL2028643

SCHEMBL2028643

Cc1ccc(CC(N)C(=O)O)c(O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.62
USP2 O75604 3/20 0.62
ALOX15 P16050 3/20 0.62
HSD17B10 Q99714 3/20 0.62
HIF1A Q16665 3/20 0.62
LMNA P02545 3/20 0.62
MAPT P10636 3/20 0.62
BLM P54132 3/20 0.62
PMP22 Q01453 3/20 0.62
KMT2A Q03164 3/20 0.62
RECQL P46063 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
CYP3A4 P08684 2/20 0.62
PKM P14618 2/20 0.62
NFKB1 P19838 2/20 0.62
ALDH1A1 P00352 2/20 0.62
NPSR1 Q6W5P4 2/20 0.62
MEN1 O00255 2/20 0.62
RGS12 O14924 1/20 0.62
CYP2C9 P11712 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2028640 1.00 KDM4E (0.62) KDM4EUSP2ALOX15HSD17B10HIF1A
SCHEMBL2028058 1.00 KDM4E (0.62) KDM4EUSP2ALOX15HSD17B10HIF1A
SCHEMBL2032864 0.87 THRB (0.62) KDM4EUSP2ALOX15HSD17B10HIF1A
SCHEMBL2033125 0.87 THRB (0.62) KDM4EUSP2ALOX15HSD17B10HIF1A
SCHEMBL2033124 0.87 THRB (0.62) KDM4EUSP2ALOX15HSD17B10HIF1A
SCHEMBL30543993 0.85 USP2 (0.51) KDM4EUSP2ALOX15HSD17B10HIF1A
SCHEMBL14640299 0.85 USP2 (0.51) KDM4EUSP2ALOX15HSD17B10HIF1A
SCHEMBL668470 0.85 USP2 (0.50) KDM4EUSP2ALOX15HSD17B10HIF1A
SCHEMBL668469 0.85 USP2 (0.50) KDM4EUSP2ALOX15HSD17B10HIF1A
SCHEMBL29351668 0.85 USP2 (0.50) KDM4EUSP2ALOX15HSD17B10HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10633630-B2 Acceleration of Mycobacterium growth ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2020-04-28 US disclosed
EP-3158053-B1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGES HOSPITAL MEDICAL SCHOOL (GB) 2019-03-13 EP disclosed
US-10000555-B2 Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus SEATTLE GENETICS, INC. (US) 2018-06-19 US disclosed
US-9707282-B2 Small cationic antimicrobial peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-07-18 US disclosed
US-20170121672-A1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2017-05-04 US disclosed
EP-3158053-A1 ACCELERATION OF MYCOBACTERIUM GROWTH St. George's Hospital Medical School (GB) 2017-04-26 EP disclosed
WO-2015193688-A1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2015-12-23 WO disclosed
US-20150315240-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-11-05 US disclosed
US-9017656-B2 Small cationic antimicrobial peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-04-28 US disclosed
EP-2061886-B1 Small cationic immunomodulatory peptides UNIV BRITISH COLUMBIA (CA) 2014-05-07 EP disclosed
US-8343475-B2 Small cationic antimicrobial peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-01-01 US disclosed
US-8343928-B2 Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus SEATTLE GENETICS, INC. (US) 2013-01-01 US disclosed
US-8343928-B2 Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus SEATTLE GENETICS, INC. (US) 2013-01-01 US disclosed
US-20110236429-A1 Small Cationic Antimicrobial Peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-09-29 US disclosed
US-20110150917-A1 Small Cationic Antimicrobial Peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2011-06-23 US disclosed
EP-2061886-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES The University of British Columbia (CA) 2009-05-27 EP disclosed
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus SEATTLE GENETICS, INC. (US) 2009-01-15 US disclosed
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus SEATTLE GENETICS, INC. (US) 2009-01-15 US disclosed
WO-2008151434-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-12-18 WO disclosed
WO-2008022444-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus MMAB, DNPEP, MARCKS KDM4E 729/4885USP2 3029/4885ALOX15 4410/4885
US-10000555-B2 Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus PTMS, MMAB, DNPEP KDM4E 608/4885USP2 2896/4885ALOX15 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.